Aprea Therapeutics, Inc. (APRE)
0.7943
-0.01
(-1.49%)
USD |
NASDAQ |
Sep 04, 16:00
0.7902
0.00 (0.00%)
After-Hours: 20:00
Aprea Therapeutics Research and Development Expense (Quarterly) : 2.462M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.462M |
| March 31, 2026 | 1.611M |
| December 31, 2025 | 1.009M |
| September 30, 2025 | 1.639M |
| June 30, 2025 | 1.912M |
| March 31, 2025 | 2.483M |
| December 31, 2024 | 2.359M |
| September 30, 2024 | 2.846M |
| June 30, 2024 | 2.558M |
| March 31, 2024 | 1.600M |
| December 31, 2023 | 2.046M |
| September 30, 2023 | 2.123M |
| June 30, 2023 | 2.203M |
| March 31, 2023 | 1.256M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.5314M |
| September 30, 2022 | 1.118M |
| June 30, 2022 | 6.812M |
| March 31, 2022 | 4.090M |
| December 31, 2021 | 4.462M |
| September 30, 2021 | 6.016M |
| June 30, 2021 | 6.654M |
| March 31, 2021 | 6.764M |
| December 31, 2020 | 9.328M |
| September 30, 2020 | 8.761M |
| June 30, 2020 | 10.69M |
| March 31, 2020 | 9.096M |
| December 31, 2019 | 8.042M |
| September 30, 2019 | 4.910M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Zymeworks, Inc. | 27.44M |
| Rhythm Pharmaceuticals, Inc. | 43.38M |
| Onconetix, Inc. | 0.0034M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |